World News Now: Affordable Medical Insurance >
   
      
Home | Login | Feeling Stressed? | FAQ's | Contact us    
Studies on HIV
Heterosexual HIV cases increasing
HIV teens 'taking more sex risks'
Tough challenges remain in Aids fight
HIV blips 'no cause for concern'
HIV parents 'limit child kisses'
Drug-resistant HIV strain found
Gene clue to HIV origin in humans
How safe are the drugs we take?
HIV can be flushed out of hiding
Key HIV-fighting genes identified
Women bearing the brunt of HIV
Heart drugs 'may slow down HIV'
Chemicals may damage male babies
Toxins Pass Disease To Next Generation
Register for News
Links

Tough challenges remain in Aids fight

Nearly 90 million Africans could be infected by the HIV virus in the next 20 years if more is not done to combat the epidemic, the UN has warned.

Only a small percentage of Aids funding goes into vaccine research

It estimates the next two decades could see 89 million new cases of the disease in Africa - or up to 10% of the continent's population.

The UN recommends a committed campaign against HIV/Aids - and $200 billion of investment - to stem its spread.

It is a dynamic picture and one of the biggest global challenges the international community has had to face.

Funding

Global funding for HIV/Aids has tripled in the past four years from a little over US$2 billion to $6billion.

Yet it still falls far short of the UNAids estimate.

With more money now in the system, divisions are emerging about how it should best be spent.

The Bush administration in the US has committed $15 billion to fight HIV/Aids. It's an impressive sum.

But it has come in for criticism from some aid agencies for pushing programmes that use brand name anti-retroviral drugs which are more expensive than their generic counterparts.

It has also been under fire for pursuing an agenda which gives priority to projects that promote sexual abstinence over condom use.
Finding a safe effective vaccine is the holy grail in HIV/Aids research

Some commentators say this is irrelevant for women in parts of Africa, for whom the biggest risk is of getting HIV is having a partner who sleeps around.

But others argue that even money with strings attached is welcome at a time when the epidemic shows little sign of waning.

Anthony Fauci - the US government's key advisor on HIV/Aids argued at the International Aids Conference in Bangkok in July that the logic behind the Bush programme was to maintain accountability and control over how US taxpayers' money is spent.

Meanwhile UN Secretary General Kofi Annan ruffled feathers when he countered that the American unilateral approach was undermining the Global Fund - an international mechanism to raise cash for HIV/Aids work, which is struggling to meet its financial targets.

That dispute has not really been resolved but there is now a concerted international effort to co-ordinate Aids funding in a more orderly manner.

Drugs

The cost of a year's anti-retroviral treatment has fallen substantially, yet nine out of 10 people who need the medicines are still not getting these life-saving treatments.

The World Health Organization has set an ambitious target of getting three million people onto the drugs by the end of 2005.


But there are real doubts whether this is achievable, given current funding levels. Aid agencies say that it is entirely possible to meet that deadline but what is needed is the political will to roll drugs out on a massive scale.

Access to anti-Aids drugs is spreading rapidly in many developing countries, the World Health Organization says.

Some 700,000 people in poor countries were taking the drugs by December 2004 - a 50% rise in six months, its latest report said.

Good progress had also been made in sub-Saharan Africa and parts of Asia.

But the situation was less satisfactory in eastern Europe, central Asia, North Africa and the Middle East.

WHO said major obstacles remained, including a funding gap of $2 billion.

It is not simply about distributing pills.

Christian Aid is one of the charities warning that without proper investment to build hospitals and train staff, sustaining anti- retroviral treatment in the long term will be hard.

Anti-retrovirals need to be taken consistently and widespread failure to do this could lead to major drug resistance and a reduction in treatment options for infected patients.

Vaccines

Finding a safe effective vaccine is the holy grail in HIV/Aids research but is proving a difficult challenge and it is unlikely that we will see effective immunisations available before the end of the decade.
Aside from the scientific difficulties, there are also enormous financial challenges

The world's richest man, Bill Gates, who has committed $260 million towards an Aids vaccine said he would be surprised if there was a vaccine within a decade and said if that happened he would "eat his hat".

There are currently some 30 different Aids vaccines undergoing trials.

These experiment with different approaches, aiming either to disable the Aids virus or prevent it from entering human cells and multiplying.

Aside from the scientific difficulties of HIV vaccine research, there are also enormous financial challenges.
I would have liked to see more discussion on HIV/Aids. For us in Africa that is the greatest threat to development

Amboka Wameyo, Tanzania

IAVI, the International Aids Vaccine Initiative points out that only 1% of global research and development funding is being channelled into finding an Aids vaccine.

The British government has already indicated that it intends to push Aids vaccine research up the political agenda, backing it up with a promise of more funding.

If indeed it does deliver, it could be a lasting legacy that finally turns the tide on an unrelenting epidemic.


Source: BBC News

Site Map American Healthcare Foundation : HomePrivacy & Terms

An Educational Program of The American Healthcare Foundation
© 2004, 2005 The American Healthcare Foundation

Disclaimer: This site is provided for general information only, and is not a substitute for the medical advice of your own doctor or other health care professional. This site is not responsible or liable for any diagnosis made by a user based on the content of this website. This site is not liable for the contents of any external internet sites listed, nor does it endorse any commercial product or service mentioned or advised on any of such sites. Always consult your own doctor.


support